Who's Who in Life Sciences - 2011

June 4, 2011

Every business sector has influential players, whether they are in the public eye or wield their influence behind the scenes. In a monthly feature that runs in the first issue of the month, through October, IBJ is identifying those people in eight different industry categories.

Formidable brainpower sums up the individuals included in our list of Who’s Who in Life Sciences. While our other lists have been confined to the greater Indianapolis area, this list stretches well beyond, recognizing the regional nature of this field. In this predominately peer-nominated and peer-reviewed process, we’ve opened the field to doctors, researchers, attorneys, entrepreneurs and more. We should note that there will be a later list dedicated to health care and benefits.

Carrie Bates

Carrie Bates, 54
Managing Partner
Triathlon Medical Ventures

Carrie Bates had known the three managing partners of Cincinnati-based Triathlon Medical Ventures for a number of years when they approached her about joining their company. The trio believed that Triathlon, one of the largest venture-capital companies in the Midwest focused exclusively on life sciences, should have a senior person in key Midwest cities. Bates was their choice for the position in Indianapolis, and she joined the company in 2003. Bates sits on the boards of several of Triathlon’s portfolio companies: CS-Keys Inc., Expanding Orthopedics Inc. and Mitralign Inc. She was on the board of Remon Medical Technologies until Boston Scientific acquired it.

Before joining Triathlon, Bates ran Compass, the Silicon Valley venture and business development group operated by Guidant Corp., formerly based in Indianapolis. There, she led more than 20 investments and other transactions. Under her leadership, Guidant’s neurovascular incubator was launched and subsequently moved into an operating division. Bates began her career at Indianapolis-based Eli Lilly and Co., where she was a pharmaceutical sales representative, manager of business development and ultimately director of finance for Advanced Cardiovascular Systems Inc., which Lilly purchased.

Bates serves on the board of the MidAmerica Health care Investors Network and the advisory board of Purdue University’s Burton D. Morgan Center for Entrepreneurship, the economic advisory board for Purdue’s Emerging Innovation Fund, Indiana University’s Kelley School of Business Life Science Industry Advisory Board and the Indiana Venture Club board. She also has been a judge for Purdue’s Burton D. Morgan Business Plan and National Life Science Business Plan competition. Bates has been a guest lecturer at both IU and Purdue.

Raised in Indiana, Bates graduated from the University of Evansville, with a bachelor’s in both computer science and finance. She obtained her MBA from the Stanford Graduate School of Business. She is a certified public accountant as well. When she’s not up to her elbows in business, Bates may be in the garden, “getting my hands dirty,” she says. She holds a Master Gardener designation from Purdue. She also enjoys long-distance walking with her husband and friends.

D. Craig Brater

D. Craig Brater, 65
Dean of Medicine
Vice President of University Clinical AffairsIndiana University

Craig Brater became dean of the Indiana University School of Medicine in 2000 and vice president of University Clinical Affairs in 2010. During his time as dean, the IU School of Medicine has increased the number of students it serves, its level of research funding, and the number of faculty who teach, see patients and conduct research.

Further, more than 600,000 square feet of space has been added to the school, ranging from multipurpose facilities in Fort Wayne and South Bend to the largest research building constructed at IU’s Indianapolis campus. Brater led the team that created the $155 million Indiana Genomic Initiative, funded by grants from Indianapolis-based Lilly Endowment Inc., which supported the recruitment of scientists and other research initiatives. In 2009, he led a team to create the Physician Scientist Initiative, which was funded by a $50 million grant from Lilly Endowment.

A native of Oak Ridge, Tenn., Brater attended undergraduate and medical school at Duke University, completed his internship at Duke and his residency at the University of California-San Francisco. Following a fellowship and a year as a junior faculty member at UCSF, Brater spent nine years on the faculty of the University of Texas Southwestern Medical Center. In 1986, he joined the faculty of the IU School of Medicine, where he began the Division of Clinical Pharmacology in the Department of Medicine. Four years later, he was selected to chair the Department of Medicine, the largest department in the school. In 2000, he was named the ninth dean of the school.

Brater is president of the board of BioCrossroads, a central Indiana life sciences advocacy group. He either is or has been president of the American Society for Clinical Pharmacology and Therapeutics, the Association of Professors of Medicine, the Central Society for Clinical Research, the U.S. Pharmacopoeia and the Alliance for Academic Internal Medicine. He also serves on the boards of IU Health and the Riley Children’s Foundation. In 2000, his alma mater conferred upon him the Duke Medical Alumni Award in recognition of his contributions to academic medicine.

Brater and his wife, Stephanie, have one daughter, who lives in Florida. The Braters are actively involved in the Indiana University-Moi University Faculty of Health Sciences exchange program in Kenya. Through this program, they met their Kenyan “son,” Michael, who has completed undergraduate and public health training at IUPUI and now works in public health in Malawi.

Darren Carroll

Darren Carroll, 49
Vice President of Corporate Business Development
Eli Lilly and Co.

About 16 years ago, Indianapolis-based Eli Lilly and Co. lured native New Yorker Darren Carroll out of his New York law practice and to Indiana. Carroll had been practicing health care technology law at the time, and Lilly had recently acquired Arizona-based PCS, a large pharmacy-benefits-management company, along with some other health care IT companies. Carroll became legal counsel for that area of Lilly and later for the Prozac team during the height of that medicine’s successful run. He describes it as “an absolutely amazing experience.”

Carroll, though, hadn’t finished his run in the Northeast. He started Innocentive, a Lilly subsidiary at the time and ran it as CEO in the Boston area. When that company was spun off in 2005, Carroll returned to Lilly here. Today, Carroll is responsible for all business development, venture-capital and alliance-management activities for the company. He has also been vice president of new ventures, which includes the fund groups Lilly Ventures and Lilly Asian Ventures, the first venture-capital group of its kind in the pharmaceutical industry.

Carroll is chairman of the advisory board for the Indiana Future Fund and the INext Fund. He is a member of the board and executive committee of BioCrossroads, a central Indiana life sciences advocacy group. He also serves on the investment committee of the Indiana Seed Fund. He has served as member of the boards of Lilly Ventures and Lilly Asian Ventures portfolio companies. Carroll holds a bachelor’s from Syracuse University; a master’s of public administration from the Maxwell School of Syracuse, where he is a member of the board of advisors; and a law degree from Syracuse University College of Law.

Kenneth Cornetta

Kenneth Cornetta, 54
Joe C. Christian Professor of Medical and Molecular Genetics
Indiana University School of Medicine

In addition to his duties at the Indiana University School of Medicine, Kenneth Cornetta is known for being co-founder, along with Butch Mercer, of Rimedion Inc., a vector technology company that is developing “orphan” drugs that treat rare, life-threatening genetic diseases, such as certain forms of cancer and blood disease. He is on the company’s scientific advisory board.

Cornetta received a bachelor’s in biological sciences from the State University of New York at Albany and his medical degree from Albany Medical College in 1982. He completed an internal medicine residency at IU and served as chief medical resident at Wishard Memorial Hospital. From 1986 until 1989, he was a National Research Service Award fellow at the National Heart, Lung and Blood Institute in Bethesda, Md., where he participated in the first approved clinical trial of a human gene transfer.

Next, Cornetta completed a hematology fellowship at the University of Wisconsin- Madison, then joined the faculty of IU, initially in the Department of Medicine. He served as director of the IU bone marrow transplant program from 1994 until 2001. In 2002, he became chairman of the Department of Medical and Molecular Genetics.

As director of the Indiana University Vector Production Facility, Cornetta seeks to develop viral vectors for use in early-phase clinical gene-therapy applications. His laboratory is funded through the National Institutes of Health and has produced more than 20 Phase I and II trials throughout the United States. Cornetta is on the editorial boards of a variety of gene-therapy journals and in 2010 served as president of the American Society of Gene and Cell Therapy. He also serves on the board of BioCrossroads, a central Indiana life sciences advocacy group.

Beyond work, Cornetta spends his free time visiting his four children and daughter-in-law “who are dedicating their lives to civic causes in the U.S. and abroad.”


Recent Articles by IBJ Staff

Comments powered by Disqus